Antibody

45개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved45 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleJiangsu HengruiPhase 2

Camrelizumab+cetuximab+chemotherapy (Camrelizumab+cetuximab+chemotherapy)

Squamous Cell Carcinoma of Head and Neck · Squamous Cell Carcinoma of Head and Neck

#SquamousCellCarcinomaofHeadandNe#Antibody#Phase2#monoclonal-antibody#Jiangsu
Trials 1Status Active
AntibodyLimited DatastaleMedical College of WisconsinPhase 1

atezolizumab (Tecentriq, Concurrent Atezolizumab)

Head and Neck Neoplasm · Head and Neck Neoplasm

#HeadandNeckNeoplasm#Antibody#Phase1#monoclonal-antibody#Medical
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

Dalpiciclib+cetuximab (Dalpiciclib+cetuximab)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent/Metastatic Head and Neck Squam

#RecurrentMetastaticHeadandNeckSq#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Active
AntibodyLimited DatastaleShanghai Ninth People's Hospita…Phase 2

Dalpicilib combined with cetuximab (Dalpicilib combined with cetuximab)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent/Metastatic Head and Neck Squam

#RecurrentMetastaticHeadandNeckSq#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Recruiting
AntibodyLimited DatastaleBoehringer IngelheimPhase 1

Ezabenlimab (Ezabenlimab)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#Boehringer
Trials 1Status Recruiting
AntibodyLimited DatastaleGeneMedicine Co., Ltd.Phase 2

Part C (GM103 and Pembrolizumab, GM103 and Pembrolizumab (Part C))

Head and Neck Cancer; Malignant Melanoma · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#monoclonal-antibody#MalignantMelanoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 + nivolumab)

Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#HeadandNeckCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleAssociazione Volontari Pazienti…Phase 3

INDUCTION CTx (TPF, INDUCTION CTx, INDUCTION CTx(TPF)+(RT+CETUXIMAB))

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Associazione
Trials 1Status Active
AntibodyLimited DatastaleUniversity of Colorado, DenverPhase 1

IPI-926 and Cetuximab (IPI-926 and Cetuximab)

Recurrent Head and Neck Cancer · Recurrent Head and Neck Cancer

#RecurrentHeadandNeckCancer#Antibody#Phase1#monoclonal-antibody#University
Trials 1Status Active
AntibodyLimited DatastaleGroupe Oncologie Radiotherapie …Phase 3

Ligufalimab (Ligufalimab)

Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) · Squamous Cell Carcinoma Head and Neck Ca

#SquamousCellCarcinomaHeadandNeck#Antibody#Phase3#monoclonal-antibody#Groupe
Trials 1Status Recruiting
AntibodyLimited DatastaleLei LiuPhase 2

MRG003 combined with Pucotenlimab (MRG003 combined with Pucotenlimab)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Lei
Trials 1Status Recruiting
AntibodyLimited DatastaleLei LiuPhase 2

MRG003 combined with Pucotenlimab+Cisplatin (MRG003 combined with Pucotenlimab+Cisplatin)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Lei
Trials 1Status Recruiting
AntibodyLimited DatastaleMerckPhase 3

pembrolizumab (Keytruda, PD-1 mAb, Pembrolizumab/Finotonlimab, PD-1 mAb (Pembrolizumab/Finotonlimab) + chemothearpy)

Squamous Cell Carcinoma of Head and Neck · PD-1

#PD-1#Antibody#Phase3#monoclonal-antibody#SquamousCellCarcinomaofHeadandNe+1
Trials 1Status Recruiting
AntibodyLimited DatastaleMerus B.V.Phase 3

Petosemtamab (Petosemtamab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Merus
Trials 1Status Recruiting
AntibodyLimited DatastaleLG ChemPhase 1

atezolizumab (Tecentriq, Phase 1b: LB-LR1109 and Atezolizumab)

Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC) · Non-small Cell Lung Cancer(NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Phase1#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAssociazione Volontari Pazienti…Phase 3

RT+CETUXIMAB (RT+CETUXIMAB)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Associazione
Trials 1Status Active
AntibodyLimited DatastalePresage BiosciencesPhase 1

TAK-981 + Avelumab (TAK-981 + Avelumab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase1#monoclonal-antibody#Presage
Trials 1Status Active
AntibodyLimited DatastalePresage BiosciencesPhase 1

TAK-981 + Cetuximab (TAK-981 + Cetuximab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase1#monoclonal-antibody#Presage
Trials 1Status Active
AntibodyLimited DatastaleTJ Biopharma Co., Ltd.Phase 2

pembrolizumab (Keytruda, TJ107 +Pembrolizumab)

Triple-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#Antibody#Phase2#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

TPF, radiotherapy and cetuximab (TPF, radiotherapy and cetuximab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active

2 / 3 pages

← PreviousNext →